(1 reference)-
- Target Alle EGFRviii (EGFRv3) Produkte
- EGFRviii (EGFRv3) (EGFR vIII (EGFRv3))
- Sequenz
- One-letter code: LEEKKGNYVV TDHC, Three-letter code: {Leu}{Glu}{Glu}{Lys}{Lys}{Gly}{Asn}{Tyr}{Val}{Val}{Thr}{Asp}{His}{Cys
- Reinheit
- > 95 %
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Lagerung
- -20 °C
-
-
: "EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma." in: Cancer research, Vol. 70, Issue 15, pp. 6303-12, (2010) (PubMed).
-
: "EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma." in: Cancer research, Vol. 70, Issue 15, pp. 6303-12, (2010) (PubMed).
-
- Target
- EGFRviii (EGFRv3) (EGFR vIII (EGFRv3))
- Hintergrund
- The epidermal growth factor receptor variant III (EGFRvIII) is a consistent tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms. As such it represents a truly tumor-specific target for antitumor immunotherapy.
- Molekulargewicht
- 1634.82
-
Sie sind hier:
